Abstract
Background The COVID-19 pandemic due to SARS-CoV-2 infection can produce Acute Respiratory Distress Syndrome as a result of a pulmonary cytokine storm. Antihistamines are safe and effective treatments for reducing inflammation and cytokine release. Combinations of Histamine-1 and Histamine-2 receptor antagonists have been effective in urticaria, and might reduce the histamine-mediated pulmonary cytokine storm in COVID-19. Can a combination of Histamine-1 and Histamine-2 receptor blockers improve COVID-19 inpatient outcomes?
Methods A physician-sponsored cohort study of cetirizine and famotidine was performed in hospitalized patients with severe to critical pulmonary symptoms. Pulmonologists led the inpatient care in a single medical center of 110 high-acuity patients that were treated with cetirizine 10 mg b.i.d. and famotidine 20 mg b.i.d. plus standard-of-care.
Results Of all patients, including those with Do Not Resuscitate directives, receiving the dual-histamine receptor blockade for at least 48 hours, the combination drug treatment resulted in a 16.4% rate of intubation, a 7.3% rate of intubation after a minimum of 48 hours of treatment, a 15.5% rate of inpatient mortality, and 11.0 days duration of hospitalization. The drug combination exhibited beneficial reductions in inpatient mortality and symptom progression when compared to published reports of COVID-19 inpatients. Concomitant medications were assessed and hydroxychloroquine was correlated with worse outcomes.
Conclusions This physician-sponsored cohort study of cetirizine and famotidine provides proof-of-concept of a safe and effective method to reduce the progression in symptom severity, presumably by minimizing the histamine-mediated cytokine storm. Further clinical studies in COVID-19 are warranted of the repurposed off-label combination of two historically-safe histamine receptor blockers.
Competing Interest Statement
Dr. Hogan II discloses a US patent application on dual-histamine receptor blockade in the treatment of COVID-19, issued patents on dual-histamine receptor blockade in the treatment of diarrhea, and ownership in a biomedical business related to the latter; Dr. Cannon none; Dr. Rappai none; Dr. Studdard reports personal fees from American College of Chest Physicians, unrelated to the submitted work; Dr. Hogan III none; Dr. Paul discloses ownership in unrelated biomedical-related businesses and consulting with numerous pharmaceutical companies; and Dr. Dooley discloses ownership in unrelated biomedical-related businesses.
Clinical Trial
This is an investigator initiated (physician sponsored) cohort study; IRB exemption status was approved by the Baptist IRB board as IRB # 20-49. The revised manuscript (06-30-2020) states "All patients were treated in a single hospital operated by Baptist Health Systems, with IRB approval (IRB # 20-49 exemption) for retrospective access to patient data." Trial registry is not required, as it is not a prospective trial.
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Baptist Health Systems approved the IRB exemption as IRB# 20-49, permitting access to patient data for this physician-sponsored retrospective cohort study. (We are exempt regarding questions #3 and #4 following.)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
(1) In the Discussion and Conclusion the cohort of 110 patients on Famotidine + Cetirizine was compared in greater detail with the cohorts of 84 and 83 patients on Famotidine alone in a published report from New York City and an article in press from Hartfort. Emphasis was on the higher acuity and comorbidity of our 110 patient cohort relative to the two other retrospective studies. (2) New paragraph on dexamethasone in the Discussion, published subsequent to the original preprint. (3) Plus minor edits.
Data Availability
The 110 patient cohort data spreadsheet will be made available to the public upon acceptance of the manuscript. An Excel spreadsheet file will be available. Reference regarding guidance for cohort or case series medical publications: "Appropriate Use and Reporting of Uncontrolled Case Series in the Medical Literature." J.H. Kempen, (2011) Am J Ophthalmol. 2001;151(1): 7-10.el. doi 10.1016/j.ajo.2010.08.047
